Introduction {#Sec1}
============

Bendamustine is an anticancer drug, which has recently evolved as an important agent for a number of lymphoid malignancies in Europe and the USA.

The drug consists of an alkylating nitrogen mustard group bound to a purine-like benzimidazole ring, and because of this unique bifunctional structure the bendamustine activity profile is significantly different from classical alkylators. Although the precise mechanism of action has not been elucidated yet, it is known that bendamustine induces DNA cross-linking and DNA breaks and induces cell death by apoptosis through intrinsic and extrinsic pathways, which in turn may deregulate the cell cycle and lead to a "mitotic" catastrophe \[[@CR1]\]. Preclinical studies and clinical observations suggest that bendamustine has limited cross-resistance with other alkylating agents and demonstrates significant synergism with anti-CD20 monoclonal antibody rituximab and purine analogues \[[@CR2], [@CR3]\].

Based on two multicentre randomised studies, bendamustine has received approval for second-line therapy in relapsed/refractory indolent non-Hodgkin lymphoma (NHL) \[[@CR4], [@CR5]\]. A growing body of evidence suggests good efficacy and acceptable tolerability of bendamustine as the first-line option for indolent lymphoma, mantle cell lymphoma (MCL) and selected patients with aggressive lymphoma.

This review presents data for bendamustine use in first-line therapy of NHL, taken from all available relevant articles published in the years 2006--2013, supplemented with abstracts from recent haematology and oncology scientific meetings. A summary of available data, source publications and conference abstracts is presented in Tables [1](#Tab1){ref-type="table"} and [2](#Tab2){ref-type="table"}.Table 1Bendamustine in first-line treatment for indolent or mantle cell lymphoma---prospective studiesStudyPatients (*n*)DiagnosisORR %CR %PFSRefBOP versus COP prospective phase III\
Herold 2006164FL, LPL, MCL66 versus 7622 versus 205 yrs: 59 % versus 46 %[@CR8]BR versus CHOPR prospective phase III\
Rummel 2013 StiL study549FL, MCL, LPL, MZL, SLL93 versus 9140 versus 3069.5 versus 31.2 months[@CR9]BR versus CVPR or CHOPR prospective phase III\
Flinn 2012 BRIGHT study436Indolent, MCL94 versus 8431 versus 25[@CR10]BR prospective phase II\
Luminari 201369MZL, SLL, LPL84581 yrs: 90 %[@CR14]BR + cytarabine prospective phase II\
Visco 201320MCL100952 yrs: 95 %[@CR19]RiBVD (BR + bortezomib + dexamethasone) prospective phase II\
Gressin 2013 LYSA study76 elderlyMCL8760[@CR22]BR + lenalidomide prospective phase I--II\
Jerkeman 201351MCL9779Not reached in 18-month follow-up[@CR21]BR + R maintenance prospective phase II\
Rummel 2012162LPL86[@CR9], [@CR12]BR prospective phase II\
Salar 201260MALT10098[@CR13]B + ofatumumab prospective phase II\
Fowler 201249Indolent9860[@CR17]BR + mitoxantrone prospective phase II\
Boccomini 201276 elderlyFL9675[@CR16]BR + bortezomib prospective phase II\
Flinn 201255Indolent8947[@CR15]B + ofatumumab + dexamethasone prospective II phase\
Magni 201219 elderlyMCL9489[@CR20]*B;* bendamustine, *BR;* bendamustine + rituximab, *BOP;* bendamustine + vincristine + prednisone, *COP;* cyclophosphamide + vincristine + prednisone, *CVPR;* cyclophosphamide + vincristine + prednisone + rituximab, *CHOPR;* cyclophosphamide + doxorubicin + vincristine + prednisone + rituximab, *RiBVD;* rituximab + bendamustine + bortezomib + dexamethasone, *FL;* follicular lymphoma, *LPL;* lymphoplasmacytic lymphoma, *MCL;* mantle cell lymphoma, *MZL;* marginal zone lymphoma, *SLL;* small lymphocytic lymphoma, *MALT;* mucosa-associated lymphoid tissue, *ORR;* overall response rate, *CR;* complete remission, *PFS;* progression-free survival, *Ref;* reference, *yrs;* yearsTable 2Bendamustine in first-line treatment for aggressive lymphomaStudyPatients (n), diagnosisORR  %CR  %PFS monthsOS monthsRefBR, retrospective\
Horn 201220, DLBCL, elderly55208.319.4[@CR25]BR, retrospective\
Kuntz 201015, DLBCL463314.123.1[@CR27]BR, retrospective\
Hammersen 201321 DLBCL MCL9114824[@CR28]BR, retrospective\
Walter 201215, DLBCL623869[@CR26]BR, prospective phase II\
Weidmann 201114, DLBCL, MCL elderly69547.77.7[@CR24]BR prospective phase II\
Park 201323, DLBCL, elderly93609.9[@CR29]*BR;* bendamustine + rituximab, *DLBCL;* diffuse large B-cell lymphoma, *MCL;* mantle cell lymphoma, *ORR;* overall response rate, *CR;* complete remission, *PFS;* progression-free survival, *OS;* overall survival, *Ref;* reference

Indolent lymphoma {#Sec2}
=================

Low-grade lymphoma, considered as an incurable disease, represents about 40 % of all NHLs. Rituximab in combination with chemotherapy, usually a CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone) regimen, is a standard first-line treatment, especially in follicular lymphoma subset \[[@CR6]\]. Encouraging results of bendamustine in relapsed or refractory indolent NHL have drawn attention to the first-line use of the drug in this setting. German Haematology Outpatient Centres have reported a continuous increase in the use of bendamustine in combination with rituximab (BR) as upfront therapy in patients with indolent NHL, despite no European Medicines Agency (EMA) approval for this indication \[[@CR7]\].

The first randomised study evaluating the effectiveness of bendamustine in treatment-naive indolent lymphoma patients was published in 2006 \[[@CR8]\]. The drug (bendamustine), in combination with vincristine and prednisone (BOP), was compared with a COP (cyclophosphamide, vincristine, prednisone) regimen in 164 patients with follicular lymphoma, MCL and lymphoplasmacytic lymphoma (LPL). There were no statistically significant differences between groups with respect to overall response rate (ORR) (BOP vs. COP: 66 vs. 76 %; *p* = 0.1) and overall survival (BOP vs. COP: 61 vs. 46 %; *p* = 0.2). The median time to progression was significantly longer in BOP responders (84 months) than in those who responded to the COP regimen (28 months), *p* = 0.0369, which translated into the probability of 5-year progression-free survival (PFS) as 59 % versus 46 %, respectively. Additionally, both haematological and non-haematological complications were less common and less severe in the BOP group than in the COP group (Table [3](#Tab3){ref-type="table"}).Table 3Haematological and non-haematological toxicity of bendamustine-based regimensStudyPatients diagnosisHaematological toxicity % grade 3--4Non-haematological toxicity % grade 3--4RefBOP versus COP prospective phase III\
Herold 2006164Anaemia10 versus 13Alopecia4 versus 48[@CR8]FL, LPLThrombocytopenia19 versus 34Vomiting0 versus 1MCLLeucopenia4 versus 1Neuropathy1 versus 0BR versus CHOPR prospective phase III\
Rummel 2013 StiL study549Anaemia3 versus 5Alopecia\*0 versus 100[@CR9]FL, LPLLeucopenia37 versus 72Neuropathy\*7 versus 29MZL, SLL, MCLThrombocytopenia5 versus 6Infection\*37 versus 50BR versus CVPR or CHOPR prospective phase III\
Flinn 2012 BRIGHT study436Anaemia\*5 versus 5Alopecia\*4 versus 51[@CR10]IndolentLeucopenia\*39 versus 87Vomiting\*29 versus 13MCLThrombocytopenia\*10 versus 12Neuropathy\*14 versus 44Infection\*55 versus 57RiBVD prospective phase II\
Gressin 201376Anaemia2Fatigue5[@CR22]MCLNeutropenia21Diarrhoea8ElderlyThrombocytopenia15Neuropathy4\* All grades

More recently, an important phase III study comparing bendamustine with rituximab (BR) to CHOPR (cyclophosphamide, doxorubicine, vincristine, prednisone, rituximab) regimen was presented \[[@CR9]\]. Following the treatment for 549 patients with indolent or MCL, ORR was similar for BR and CHOPR groups (93 vs. 91 %), complete remission (CR) was significantly increased in the BR group (40 vs. 30 %, *p* = 0.021) and PFS was significantly longer in the BR group (69.5 vs. 31.2 months, *p* \< 0.0001). There were fewer toxic complications after BR therapy.

Another randomised study compared results of BR therapy with CVPR (cyclophosphamide, vincristine, prednisone, rituximab) or CHOPR in the treatment for 436 patients with indolent NHL or MCL \[[@CR10], [@CR11]\]. ORR was 94 % after BR in comparison with 84 % after CVPR or CHOPR regimen, and CR rate was higher for the BR group (31 vs. 25 %, *p* = 0.0225). Analysis indicated that adverse reactions were reported for both BR and CVPR or CHOPR therapy (Table [3](#Tab3){ref-type="table"}). Subgroup analysis for indolent lymphoma (MCL excluded), revealed similar results with respect to CR rate for BR and CVPR or CHOPR regimens (28 vs. 25 %).

BR is effective in the treatment for patients with LPL, as was seen in the StiL study and confirmed by Rummel in a phase II trial with 86 % of ORR, where BR therapy was followed by rituximab maintenance therapy \[[@CR9], [@CR12]\]. Another subgroup of NHL patients with mucosa-associated lymphoid tissue (MALT) lymphoma, treated in a Spanish study with BR, achieved 98 % CR rate, and overall response was observed in 100 % \[[@CR13]\].

A number of ongoing and recently finished clinical trials investigating bendamustine in combination with other drugs (mitoxantrone, lenalidomide, bortezomib) reveal promising ORR and CR in the indolent lymphoma setting \[[@CR13]--[@CR17]\]. These results translate into prolonged progression-free survival, which today is considered a treatment success in low-grade NHL patients.

Bendamustine has not yet been approved as a first-line therapy of NHL in Europe, but as the preliminary reports on its use in treatment-naïve patients are encouraging, there are an increasing number of centres using bendamustine as a compassionate drug \[[@CR7], [@CR18]\]. A retrospective multicentre analysis of the Spanish Registry of indolent NHL patients revealed high effectiveness, with an ORR of 95 % and CR of 66.5 %, and favourable tolerance profile of BR regimen in newly diagnosed indolent lymphoma patients.

Mantle cell lymphoma {#Sec3}
====================

Mantle cell lymphoma has poorer prognosis and outcome than other subtypes of NHL. Young and fit patients are usually treated with intensive therapy followed by autologous stem cell transplantation. A growing body of data indicates a high response rate after bendamustine in patients with MCL, not only in rescue therapy but also as upfront treatment. In a phase II study with bendamustine in combination with cytarabine and rituximab in untreated MCL patients, ORR was 100 % and 2-year PFS was 95 % \[[@CR19]\]. Subgroup analysis of prospective, randomised studies has also shown superiority of BR regimen in comparison to CHOPR-like treatment \[[@CR9]\]. The CR rate in the BRIGHT study was 27 % for BR versus 50 % for CHOPR or CVPR regimen, and PFS (progression-free survival) in the StiL study for BR was 35.4 months versus 22.1 months for CHOPR (*p* = 0.0044).

Ongoing clinical studies are evaluating bendamustine in combination with lenalidomide, ibrutinib, temsirolimus or ofatumumab in MCL therapy \[[@CR20]--[@CR22]\]. Preliminary results from the LYSA trial, including 76 elderly patients newly diagnosed with MCL, indicated that 4 cycles of rituximab, bendamustine, bortezomib, dexamethasone (RiVBD) yielded 87 % ORR rate and 60 % CR rate \[[@CR22]\]. Fifty-one elderly patients (\>65 years) with previously untreated MCL grade II--IV were provided with BR combined with lenalidomide. Following six cycles of the treatment, the ORR was 97 %, CR was 79 % and OS after 2 years amounted to 87 % \[[@CR21]\].

The results of clinical studies published thus far, assessing the use of bendamustine in upfront treatment for MCL, seem to indicate a risk-stratified approach, based on the MCL international prognostic index (MIPI). Bendamustine in combination with rituximab could be recommended as a first-line therapy in elderly MCL patients with high or intermediate MIPI risk \[[@CR23]\].

Aggressive lymphoma {#Sec4}
===================

The combination of rituximab and cyclophosphamide, doxorubicin, vincristine and prednisone is the standard first-line treatment regimen in patients with diffuse large B-cell lymphoma (DLBCL); however, the available data do not apply to elderly or frail patients. Only a few smaller studies have investigated the role of bendamustine in this setting.

A phase II study demonstrated a CR rate of 54 % in elderly patients treated with BR as first-line therapy with a good safety profile \[[@CR24]\]. Retrospective studies confirmed the efficacy of the BR regimen in unfit DLBCL patients. Results are acceptable and manageable for toxicity; however, they seem to be generally unacceptable for PFS and overall survival \[[@CR25]--[@CR27]\]. Defining prognostic factors as GCB-subtype of DLBCL might predict a better outcome in bendamustine treated patients \[[@CR28]\]. Performance and comorbidity assessment have a great impact on the outcome of frail patients with aggressive lymphoma \[[@CR29]\].

Bendamustine safety profile {#Sec5}
===========================

The clinical studies published so far have reported fairly low or mild toxicity of bendamustine-containing regimens \[[@CR30]\]. The adverse events (AE) observed in lymphoma patients treated with bendamustine are summarised in Table [3](#Tab3){ref-type="table"}. In general, bendamustine seems to present a favourable toxicity profile, and the most common complications involve haematological events such as anaemia, leucopenia, neutropenia or thrombocytopenia. Despite being reversible, these toxicities are common, with as much as a 94 % occurrence rate for all grade events. The most frequently reported non-haematological toxicities related to bendamustine treatment include nausea, infections, fatigue, constipation, diarrhoea, headache and vomiting. A multicentre phase III clinical trial comparing first-line BR versus CHOPR revealed a much lower rate of serious AE in the BR arm than in CHOPR treated patients (49 vs. 74) \[[@CR9]\]. Moreover, a granulocyte colony-stimulating factor (G-CSF) was used only in 4 % of the patients receiving BR and in 20 % of those receiving CHOPR treatment. Similarly, non-haematological AEs were of lower grade or incidence in the BR group than in the CHOPR arm. A meta-analysis of randomised, controlled trials comparing the bendamustine-containing regimen to any other regimen demonstrated no effect of bendamustine on the rate of infection when compared to either alkylating agents or fludarabine in haematological, as well as in solid, malignancies despite, remarkably, lymphopenia \[[@CR31]\]. A few case studies were published reporting on the safety and effectiveness of the BR regimen in DLBCL patients with severe liver impairment \[[@CR32]\]. Low toxicity of bendamustine, even in these unfavourable settings, makes the drug safe and effective in special patient populations.

The exact mechanism behind bendamustine's low toxicity remains not fully understood, and additional basic research aimed at its elucidation is required. It also seems advisable to assess long-term bendamustine toxicity and its potential interactions with other second-line treatments.

Increasing interest in bendamustine as an upfront therapy has prompted a cost-effectiveness analysis of this drug. When compared to CHOPR or CVPR regimens, the BR was found to be cost-effective, and due to its more favourable toxicity profile it incurred lower costs related to AE management \[[@CR33]\].

Perspectives {#Sec6}
============

The remarkably low toxicity profile and high efficacy of bendamustine provide a basis for the use of this drug in the treatment for a variety of lymphoma subsets. Recent preclinical data and clinical studies have confirmed the activity of bendamustine in heavily pretreated patients with Hodgkin lymphoma or peripheral T-cell lymphoma \[[@CR34]\]. The efficacy of bendamustine has been evaluated in treatment for multiple myeloma, with encouraging results \[[@CR35], [@CR36]\]. These impressive observations may lead to the design of prospective trials evaluating bendamustine in upfront therapy in selected patients in these settings.

It was demonstrated that bendamustine provided clinical benefits when combined with other agents, i.e. monoclonal antibodies, purine analogues or more modern drugs such as lenalidomide, bortezomib, ibrutinib or idelalisib. There are a number of clinical trials, expected to be completed in 2014 and 2015, that are assessing the dose-limited toxicity and maximum tolerated dose of bendamustine in combination with those and other drugs. Such observations create new possibilities in the therapy of lymphoid malignancies.
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